OncoMatch

OncoMatch/Clinical Trials/NCT06627738

Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost

Is NCT06627738 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for carcinoma, non-small-cell lung.

Phase 2RecruitingCentre Antoine LacassagneNCT06627738Data as of May 2026

This is a monocentric, non-randomized, open-label, superiority phase II clinical investigation evaluating the efficacy of additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in patients with locally advanced non-small cell lung carcinoma (NSCLC), with an interim analysis.

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Small Cell Lung Carcinoma

Biomarker criteria

Excluded: EGFR positive mutation

Positive EGFR mutation

Disease stage

Required: Stage III

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

Must have received: platinum-based chemotherapy — induction (2 cycles) and concomitant (at least 2 cycles) with radiotherapy

2 cycles of induction chemotherapy (platinium-based doublet) and then at least 40 Gy of irradiation in combination with at least 2 cycles of concomitant chemotherapy (platinium-based doublet)

Must have received: radiation therapy — at least 40 Gy, with chemotherapy

at least 40 Gy of irradiation in combination with at least 2 cycles of concomitant chemotherapy (platinium-based doublet)

Lab requirements

Cardiac function

No exercise-induced dyspnea associated with heart failure ≥ NYHA III; no coronary syndrome or heart failure in last 3 months

Exercise-induced dyspnea associated with heart failure equal to or greater than stage III of the New York Heart Association (NYHA) classification [excluded]; Coronary syndrome or heart failure in the last three months [excluded]

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify